<DOC>
	<DOCNO>NCT01679158</DOCNO>
	<brief_summary>The purpose study evaluate impact minor variation Incisionless Operating Platform ( IOP ) procedural technique gastric emptying , hormone level , satiety , weight loss treatment primary obesity . It confirm , open prospective study , action mechanism `` POSE '' endoscopic treatment technique obesity , help determine maintain least 6 month follow procedure . Durability weight loss track post-POSE visit 18 month follow procedure .</brief_summary>
	<brief_title>MOTIVATE Weight Loss Study</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<criteria>1 . Has BMI &gt; 30 &lt; 40 2 . Male female â‰¥21 yr . age &lt; 60 yr . age time enrollment 3 . Patient significant weight change ( +/ 5 % total body weight ) last 6 month able lose significant weight past diet exercise . 4 . Is reasonable candidate general anesthesia 5 . Agrees additional weight loss interventional procedure liposuction least 18 month follow study enrollment agrees take prescription counter weight loss medication least 1 year . 6 . Physically mentally able comply visit schedule , ancillary testing , behavior modification ( diet exercise ) require study agrees study commitment requirement 7 . Had successful completion prescreening , nutritional educational program psychological assessment support subject appropriate bariatric surgical candidate 1 . History ( intraoperative evidence ) bariatric , gastric esophageal surgery 2 . Esophageal stricture anatomy and/or condition could preclude passage endoluminal instrument 3 . Moderate severe Gastroesophageal reflux disease ( GERD ) 4 . Known hiatal hernia &gt; 3cm history determine UGI exam endoscopy 5 . Known GI motility disorder pancreatic insufficiency/disease 6 . Intraoperative Exclusion : Active peptic ulcer hiatal hernia &gt; 3cm 7 . Pregnancy . 8 . Present Corticosteroid Use 9 . History inflammatory disease GI tract 10 . Severe coagulopathies , hepatic insufficiency cirrhosis 11 . History present use insulin insulin derivative treatment diabetes 12 . Had Type II Diabetes Mellitus ( define HgbA1c &gt; 6.0 ) great 2 year time enrollment 13 . Uncontrolled Type II DM ( HgbA1c &gt; 7.0 screening ) 14 . Patient quit smoking within last 6 month time enrollment plan quit smoke next year 15 . Patient history drug alcohol abuse actively abuse either 16 . Patient presently treat medication depression , psychosis , mood eat disorder 17 . Nonambulatory significant impairment mobility 18 . Works , first degree relative investigator , study institution , support staff involve study . 19 . Known hormonal genetic cause obesity 20 . Participating another clinical study 21 . Patient medication know impact GI motility gut hormone discontinue prior nuclear test 22 . Have work hour , family obligation transportation issue could interfere patient return scheduled evaluation , test nutritional counseling . 23 . Lives &gt; 60 kilometer investigator site . 24 . Patient able provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Using POSE treatment Obesity</keyword>
</DOC>